Dexcom (DXCM) Cash & Equivalents (2010 - 2026)

Dexcom (DXCM) has reported Cash & Equivalents for 17 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 4.66% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 4.66% decrease from a year earlier, with the FY2025 full-year figure at $917.7 million, up 51.41% from the prior year.
• Cash & Equivalents was $1.1 billion for Q2 2026 at Dexcom, down from $1.1 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.8 billion in Q3 2025 and troughed at $566.3 million in Q4 2023.
• A 5-year average of $882.1 million and a median of $793.3 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 51.67% in 2022 and soared 195.51% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $642.3 million in 2022, then decreased by 11.83% to $566.3 million in 2023, then rose by 7.03% to $606.1 million in 2024, then soared by 51.41% to $917.7 million in 2025, then gained by 20.41% to $1.1 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.1 billion (Q2 2026), $1.1 billion (Q1 2026), and $917.7 million (Q4 2025), per Business Quant data.